Efficacy of tamsulosin for treating lower urinary tract symptoms in patients with advanced prostate cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Relevance. From the moment of their first use to the present day, α-adrenoblockers remain the most popular medication in urology. Indications for their clinical use for various pathological conditions are constantly expanding. Aim. To compare the efficacy of androgen deprivation therapy (ADT) alone and ADT with concomitant use of tamsulosin in treating lower urinary tract symptoms (LUTS), and to estimate the efficacy and safety of tamsulosin in relieving voiding dysfunction symptoms in patients with advanced PCa treated for 6 months. Materials and methods. This paper presents data from a randomized, open, single-center trial that evaluated the efficacy and safety of tamsulosin co-administered with ADT for LUTS in patients with advanced prostate cancer. The study comprised 50 people aged below 75 years. In the first group of patients (n=25), ADT was used as a monotherapy, in the second group (n=25) ADT with concurrent administration of the α-adrenoblocker. The duration of treatment was 6 months. Results. Both groups showed an improvement in the severity of LUTS, decrease in the total I-PSS score and residual urine volume and increase in the urinary flow rate. At the same time, co-administration of ADT and α-adrenoblocker resulted in greater and faster relief of LUTS than using ADT alone. There were no significant side effects in any of the groups. Conclusions. Co-administration of ADT and the α-blocker is an effective and safe treatment for advanced prostate cancer in patients with LUTS.

Full Text

Restricted Access

About the authors

A. V Govorov

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: dr.govorov@gmail.com
Dr.Med.Sci., Associate Professor at the Department of Urology

A. O Vasilyev

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: alexvasilyev@me.com
PhD, Teaching Assistant at the Department of Urology

D. Yu Pushkar

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: pushkardm@mail.ru
corresponding member of RAS, Dr.Med.Sci., Prof., Head of the Department of Urology

References

  1. World cancer statistic in 2015. Available at: https:// cancerstatisticscenter.cancer.org/#/
  2. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ НМИРЦ Минздрава России. 2017. илл. 250 с. ISBN 978-5-85502-227-8
  3. Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, B.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ НМИРЦ Минздрава России. 2016. илл. 236 с. ISBN 978-5-85502-231-5
  4. Lehrer S., Stone N., Droller M., Stock R. Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Urol Oncol. 2002;7:73-76.
  5. Hamilton W., Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J. Gen Pract. 2004;54:617-621.
  6. Andersson S.O., Rashidkhani B., Karlberg L., Wolk A., Johansson J.E. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40,000 Swedish men. BJU Int. 2004;94:327-331.
  7. Ream E., Quennell A., Fincham L., Faithfull S., Khoo V., Wilson-Barnett J., Richardson A. Supportive care needs of men living with prostate cancer in England: a survey. Br J. Cancer. 2008;98(12):1903-1909.
  8. Peltier A., Aoun F., De Ruyter V., Cabri P., Van Velthoven R. Triptorelin in the relief of lower urinary tract symptoms in advanced prostate cancer patients: the result study. Prostate Cancer. 2015;2015:978194. doi: 10.1155/2015/978194
  9. Gravas S., Bach T., Drake M., Gacci M., Gratzke C., Herrmann T.R.W., Madersbacher S., Mamoulakis C., Tikkinen K.A.O. European Association of Urology. Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). 2017. http://uroweb.org/ wp-content/uploads/13-Non-Neurogenic-Male-LUTS_2017_web. pdf Update March, 2017.
  10. Zhang T., Wu H., Liu S., He W., Ding K. Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients Int Urol Nephrol. Published online 13 April 2017. doi: 10.1007/s11255-017-1591-1.
  11. Mommsen S., Petersen L. Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention. Scand J. Urol Nephrol. 1994;28(4):401-404.
  12. Klarskov L.L., Klarskov P., Mommsen S., Svolgaard N. Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study. Scand J. Urol Nephrol. 2012;46:37-43.
  13. Axcrona K., Aaltomaa S., da Silva C.M., Ozen H., Damber J.E., Tanko L.B., Colli E., Klarskov P. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int. 2012;110(11):1721-1728.
  14. Kyprianou N., Benning C.M. Suppression of human prostate cancer cell growth by a1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 2000;60(16):4550-4555.
  15. Michel M.C., Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J. Pharmacol. 2006;147(Suppl. 2):88-119.
  16. Oesterling J.E. LHRH agonists: a nonsurgical treatment for benign prostatic hyperplasia. J. Androl. 1991;12(6):381-388.
  17. Mason M., Maldonado Pijoan X., Steidle C., Guerif S., Wiegel T., van der Meulen E., Bergqvist P.B., Khoo V. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised noninferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol (R Coll Radiol). 2013;25(3):190-196.
  18. Langenhuijsen J.F., van Lin E.N., Hoffmann A.L., Spitters-Post I., Alfred Witjes J., Kaanders J.H., Mulders P.F. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol. 2011;29:52-57.
  19. Sanghani M.V., Schultz D., Tempany C.M., Titelbaum D., Renshaw A.A., Loffredo M., Cote K., McMahon B., D’Amico A.V. Quantifying the change in endorectal magnetic resonance imaging-de ned tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology. 2003;62:487-491.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies